Atherosclerosis is the major form of coronary heart disease and a primary cause of non-accidental death in America. Multiple risk factors contribute to arteriosclerosis such as: hypertension, elevated total serum cholesterol, low density lipoprotein (LDL) cholesterol, low levels of high density lipoprotein (HDL) cholesterol, diabetes mellitus, occlusive vascular diseases, severe obesity, and cigarette smoking. The progression of vascular atheromatous intimal fatty streaks or plaques appears to be through the intra- and extracellular accumulation of lipid in foam cells from circulating lipoproteins. The composition and levels of serum lipoproteins, molded by genetics and or environmental influences, are complex but appears to have an important role in determining the prediction of artherosclerosis. Recent development and progress in the area of post-natal gene therapy, may provide a means to alter the composition of serum lipoproteins and limit atherogenesis. The primary goals of this proposal is to develop a myogenic expression system for post-natal gene therapy, to deliver increased amounts of lipoprotein lipase in the experimental Watanabe hyperlipidemic rabbit model system and improve its lipid profile and reverse atherogenesis. In developing a strategy, we considered ex vivo approaches utilizing cellular transplantation. Although efficacious in animal studies, ex vivo gene therapy might be problematic and impractical for human application. In vivo DNA-mediated gene therapy, in which DNA vectors are presented directly to the target organs, appears, on the other hand, to be the practical choice for human gene therapy. Muscle tissue has the potential to become a primary target organ for somatic gene therapy. Muscle offers an easily accessible site for the injection of therapeutic genes and most importantly plasmid DNA can be taken up into muscle nuclei as non-integrated extrachromosomal DNA, that results in the expression of that gene for extended periods of time. In order to use muscle as a gene therapy model, it will be necessary to: (1) Develop a potent myogenic vector that elevates the level of gene expression activity several orders of magnitude over standard known vectors, in order to deal with the inefficiency of naked DNA uptake; and (2) improve vector uptake and reduce vector degradation into muscle nuclei. Through a combination of improvements in both muscle vector design and vector delivery vehicles, muscle will be a highly suitable target tissue for expression of therapeutic genes that will help to ameliorate cardiovascular disease states.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
1P01HL050422-01
Application #
3781170
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030
Waugh, J M; Li-Hawkins, J; Yuksel, E et al. (2000) Thrombomodulin overexpression to limit neointima formation. Circulation 102:332-7
Waugh, J M; Yuksel, E; Li, J et al. (1999) Local overexpression of thrombomodulin for in vivo prevention of arterial thrombosis in a rabbit model. Circ Res 84:84-92
Waugh, J M; Kattash, M; Li, J et al. (1999) Gene therapy to promote thromboresistance: local overexpression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit model. Proc Natl Acad Sci U S A 96:1065-70
Rojas-Martinez, A; Wyde, P R; Montgomery, C A et al. (1998) Distribution, persistency, toxicity, and lack of replication of an E1A-deficient adenoviral vector after intracardiac delivery in the cotton rat. Cancer Gene Ther 5:365-70
Faith, R E; Montgomery, C A; Durfee, W J et al. (1997) The cotton rat in biomedical research. Lab Anim Sci 47:337-45
Gottschalk, S; Sparrow, J T; Hauer, J et al. (1996) A novel DNA-peptide complex for efficient gene transfer and expression in mammalian cells. Gene Ther 3:448-57
Guo, Z S; Wang, L H; Eisensmith, R C et al. (1996) Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer. Gene Ther 3:802-10
Gingras, M C; Arevalo, P; Aguilar-Cordova, E (1996) Potential salmon sperm origin of the E3 region insert of the adenovirus 5 dl309 mutant. Cancer Gene Ther 3:151-4
Sparrow, J T; Monera, O D (1996) Improvements to the TMSBr method of peptide resin deprotection and cleavage: application to large peptides. Pept Res 9:218-22
Gottschalk, S; Tweten, R K; Smith, L C et al. (1995) Efficient gene delivery and expression in mammalian cells using DNA coupled with perfringolysin O. Gene Ther 2:498-503

Showing the most recent 10 out of 13 publications